Life sciences venture capital firm Forbion says that its newest portfolio company, Prilenia Therapeutics, a Naarden, Netherlands- and Herzliya, Israel-based clinical stage biotech company, has raised $62.5 million in a Series A financing round. 4 June 2020
Novo Ventures, part of Denmark’s Novo Holdings, today announced that it has led the $55 million Series B financing in UK and USA-based biotech NodThera, which is developing a new class of medicines to treat diseases driven by chronic inflammation. Nanna Lüneborg, a partner at Novo Ventures, will join the NodThera board. 3 June 2020
Canada-based precision oncology firm Repare Therapeutics has entered into an exclusive, worldwide, multi-target research collaboration with US pharma giant Bristol-Myers Squibb. 28 May 2020
US biotech Humanigen has announced that the first COVID-19 patient has been dosed in its trial of lenzilumab, the company’s anti-human granulocyte macrophage-colony stimulating factor (GM-CSF) monoclonal antibody. 15 May 2020
Cambridge, Massachusetts-based biotech Dyno Therapeutics has emerged from stealth with two strategic collaborations to develop improved gene therapies with AAV vectors based on AI (artificial intelligence) technology. 11 May 2020
Canadian biotech Quest PharmaTech saw its shares tumble 15.4% to C$0.11 by close of trading on Wednesday, after the company revealed that its subsidiary, OncoQuest, was divesting assets. 23 April 2020
Avacta has announced that, in only four weeks and well ahead of schedule, it has successfully generated multiple Affimer reagents that bind the SARS-COV-2 viral antigen. 22 April 2020
Cellphire says the Biomedical Advanced Research and Development Authority (BARDA), part of the office of the Assistant Secretary for Preparedness and Response at the US Department of Health and Human Services, has exercised its third contract option. 22 April 2020
US rare disease specialist Soligenix saw its shares rocket 89% pre-market, after it revealed it has executed an agreement for the exclusive worldwide license of CoVaccine HT, a novel vaccine adjuvant, from BTG Specialty Pharmaceuticals, a division of Boston Scientific Corp (NYSE: BSX), for the fields of SARS-CoV-2, the cause of COVID-19 and pandemic flu. 16 April 2020
Shares of Belgium’s Galapagos and Poland-based Ryvu Therapeutics both saw their shares rise this morning on news of a collaboration on the discover and development of small-molecule drugs in inflammation. 16 April 2020
The Food and Drug Administration late yesterday granted expedited approval for Jelmyto (mitomycin) for pyelocalyceal solution, a first-in-class treatment indicated for adults with low-grade upper tract urothelial cancer (LG UTUC). 16 April 2020
Canadian clinical-stage biotech Bold Therapeutics says it has initiated a research partnership with researchers from the University of Ottawa to explore the potential utility of BOLD-100, under development as an anti-cancer drug, as a novel antiviral agent. 15 April 2020
French companies LFB, formerly known as Laboratoire Francais du Fractionnement et des Biotechnologies, and biotech Xenothera have signed an agreement for the production by LFB of the first clinical batch of a drug candidate, XAV-19, developed by Xenothera for the treatment of coronavirus infections including COVID-19. 15 April 2020
Danish dermatology specialist LEO Pharma has singed a worldwide licensing deal with Taiwan-based Oneness Biotech and China’s Microbio Shanghai for the development and commercialization of the novel atopic dermatitis (AD) and allergic asthma drug candidate FB825. 15 April 2020
Sino-America biotech firm BeiGene’s were up 4.8% at HK$6,160 by close of trading yesterday, after it announced positive new trial results with its lung cancer candidate tislelizumab. 15 April 2020
Californian genetic research company MedGenome and Indian research charity SciGenom Research Foundation (SGRF) have published research into genetic susceptibility to the COVID-19 disease. 14 April 2020
Eagle Pharmaceuticals has received final approval from the US Food and Drug Administration for its novel product, Pemfexy (pemetrexed for injection), a branded alternative to Alimta. 11 February 2020
Adding to the so far unsuccessful pursuit of trying to find an effective treatment for the devasting condition, Eagle Pharmaceuticals late Monday announced that Eagle and the University of Pennsylvania (Penn) have agreed on terms of a new exclusive worldwide license agreement for the development of dantrolene sodium for the potential treatment of people living with Alzheimer’s disease, including an agreement to fund additional research and provisions regarding commercialization of products developed under the license. 14 January 2020
Emerging US biotech Tyme Technologies saw its shares leap 13.6% to $1.75 in unusually heavy volume, on news of a potential $40 million deal with Eagle Pharmaceuticals focused on the co-promotion of Tyme's lead CMBT candidate oral SM-88 in advanced cancers. 8 January 2020
Trevi Therapeutics has announced significant milestones in its clinical programs for Haduvio (nalbuphine), an investigational therapy aimed at treating chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC). 4 October 2024
Paris-based asset manager Kurma Partners has raised 140 million euros ($154 million), successfully completing the first closing of Biofund IV 4 October 2024
Singapore’s Agency for Science, Technology and Research (A*STAR) and US biotech incubator Flagship Pioneering have agree to collaborate on advancing health and sustainability outcomes in Singapore and the broader Asia Pacific region. 4 October 2024
The US Food and Drug Administration (FDA) has removed the partial clinical hold on delpacibart etedesiran (del-desiran/AOC 1001), an investigational treatment designed to address the root cause of myotonic dystrophy type 1 (DM1), under development by US biotech Avidity Biosciences . 4 October 2024
Caliway Biopharmaceuticals has successfully completed its initial public offering, raising NT$6.4 billion ($206 million), the largest IPO in Taiwan's biotech industry to date. 3 October 2024
US clinical-stage biotech Arcus Biosciences has entered into a clinical trial collaboration with AstraZeneca on renal cancer treatments. 3 October 2024
PeptiDream says that its wholly-owned PDRadiopharma subsidiary has entered into a strategic partnership with French nuclear medicines firm Curium. 3 October 2024
Shares of UK drug developer Hemogenyx Pharmaceuticals rose as much as 9% and closed up 5.9% at 1.70 pence yesterday on the news of a further investment from Prevail Partners. 3 October 2024
UK-based biotech Resolution Therapeutics has announced the completion of a £63.5 million ($76.8 million) series B financing round led by Syncona. 3 October 2024
Liquidia Corporation and Pharmosa Biopharm have amended the current exclusive licensing agreement for the development and commercialization of L606. 3 October 2024
Timing can be crucial in biotech, and any company that can help optimize radiopharmaceuticals to fight cancer is likely to a hot property right now, given the recent popularity of the field among investors and drugmakers. 2 October 2024
UK-based biotech LoQus23 Therapeutics has closed a £35 million ($43 million) series A financing round, led by Forbion, with support from SV Health Investors' Dementia Discovery Fund and Novartis Venture Fund. 2 October 2024
Privately-held UK biotech Curve Therapeutics today announced the further strengthening of its leadership team with the appointments of Andre Hoekema as chairman of the board and Cora Griffin as head of business development. 2 October 2024
NK:IO, a London startup developing a cell therapy for treating solid tumors, has announced the appointment of a permant chief executive and the finalization of a seed funding round. 2 October 2024
Spanish epigenetics firm Oryzon Genomics has announced the receipt of the official meeting minutes from a recent End-of-Phase II meeting for vafidemstat in borderline personality disorder (BPD) with the US Food and Drug Administration (FDA). 2 October 2024
Halda Therapeutics, a US biotech company advancing cancer treatments, announced the appointment of Christian Schade as president and chief executive. 1 October 2024